|
1
|
Cooper AJ, Sequist LV and Lin JJ:
Third-generation EGFR and ALK inhibitors: Mechanisms of resistance
and management. Nat Rev Clin Oncol. 19:499–514. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Robichaux JP, Le X, Vijayan RSK, Hicks JK,
Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, et al:
Structure-based classification predicts drug response in
EGFR-mutant NSCLC. Nature. 597:732–737. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
O'Kane GM, Bradbury PA, Feld R, Leighl NB,
Liu G, Pisters KM, Kamel-Reid S, Tsao MS and Shepherd FA: Uncommon
EGFR mutations in advanced non-small cell lung cancer. Lung Cancer.
109:137–144. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Frankell AM, Dietzen M, Al Bakir M, Lim
EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A,
et al: The evolution of lung cancer and impact of subclonal
selection in TRACERx. Nature. 616:525–533. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yamaguchi O, Kasahara N, Soda H, Imai H,
Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, et
al: Predictive significance of circulating tumor DNA against
patients with T790M-positive EGFR-mutant NSCLC receiving
osimertinib. Sci Rep. 13(20848)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Borgeaud M, Parikh K, Banna GL, Kim F,
Olivier T, Le X and Addeo A: Unveiling the landscape of uncommon
EGFR mutations in NSCLC-A systematic review. J Thorac Oncol.
19:973–983. 2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jiang Y, Fang X, Xiang Y, Fang T, Liu J
and Lu K: Afatinib for the treatment of NSCLC with uncommon EGFR
mutations: A narrative review. Curr Oncol. 30:5337–5349.
2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pizzutilo EG, Agostara AG, Oresti S,
Signorelli D, Stabile S, Lauricella C, Motta V, Amatu A, Ruggieri
L, Brambilla M, et al: Activity of osimeRTInib in non-small-cell
lung Cancer with UNcommon epidermal growth factor receptor
mutations: Retrospective Observational multicenter study
(ARTICUNO). ESMO Open. 9(103592)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang P, Fabre E, Martin A, Chouahnia K,
Benabadji A, Matton L and Duchemann B: Successful sequential
tyrosine kinase inhibitors to overcome a rare compound of EGFR exon
18-18 and EGFR amplification: A case report. Front Oncol.
12(918855)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ullas B, Shrinidhi N, Mansi S, Narayan S,
Parveen J, Surender D, Joslia JT and Anurag M: All EGFR mutations
are (not) created equal: focus on uncommon EGFR mutations. J Cancer
Res Clin Oncol. 149:1541–1549. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zou B, Lee VHF and Yan H: Prediction of
sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC
based on structural interaction fingerprints and multilinear
principal component analysis. BMC Bioinformatics.
19(88)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lococo F, Ghaly G, Chiappetta M, Flamini
S, Evangelista J, Bria E, Stefani A, Vita E, Martino A, Boldrini L,
et al: Implementation of artificial intelligence in personalized
prognostic assessment of lung cancer: A narrative review. Cancers
(Basel). 16(1832)2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
He B, Dong D, She Y, Zhou C, Fang M, Zhu
Y, Zhang H, Huang Z, Jiang T, Tian J and Chen C: Predicting
response to immunotherapy in advanced non-small-cell lung cancer
using tumor mutational burden radiomic biomarker. J Immunother
Cancer. 8(e000550)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Qureshi R, Basit SA, Shamsi JA, Fan X,
Nawaz M, Yan H and Alam T: Machine learning based personalized drug
response prediction for lung cancer patients. Sci Rep.
12(18935)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Harada D and Takigawa N: Oligoprogression
in non-small cell lung cancer. Cancers (Basel).
13(5823)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jackman D, Pao W, Riely GJ, Engelman JA,
Kris MG, Jänne PA, Lynch T, Johnson BE and Miller VA: Clinical
definition of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
J Clin Oncol. 28:357–360. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Abramson J, Adler J, Dunger J, Evans R,
Green T, Pritzel A, Ronneberger O, Willmore L, Ballard AJ, Bambrick
J, et al: Accurate structure prediction of biomolecular
interactions with AlphaFold 3. Nature. 630:493–500. 2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Leeuwenberg AM, van Smeden M, Langendijk
JA, van der Schaaf A, Mauer ME, Moons KGM, Reitsma JB and Schuit E:
Performance of binary prediction models in high-correlation
low-dimensional settings: A comparison of methods. Diagn Progn Res.
6(1)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yang JC, Schuler M, Popat S, Miura S,
Heeke S, Park K, Märten A and Kim ES: Afatinib for the treatment of
NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J
Thorac Oncol. 15:803–815. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang C, Zhao K, Hu S, Dong W, Gong Y, Li M
and Xie C: Clinical outcomes of gefitinib and erlotinib in patients
with NSCLC harboring uncommon EGFR mutations: A pooled analysis of
438 patients. Lung Cancer. 172:86–93. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib
versus gefitinib as first-line treatment for patients with
EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A
randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Oxnard GR, Lo PC, Nishino M, Dahlberg SE,
Lindeman NI, Butaney M, Jackman DM, Johnson BE and Jänne PA:
Natural history and molecular characteristics of lung cancers
harboring EGFR exon 20 insertions. J Thorac Oncol. 8:179–184.
2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri
S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG and Ladanyi M:
Prevalence, clinicopathologic associations, and molecular spectrum
of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Clin Cancer Res. 18:4910–4918. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li HS, Yang GJ, Cai Y, Li JL, Xu HY, Zhang
T, Zhou LQ, Wang YY, Wang JL, Hu XS, et al: Dacomitinib for
advanced non-small cell lung cancer patients harboring major
uncommon EGFR alterations: A dual-center, single-arm, ambispective
cohort study in China. Front Pharmacol. 13(919652)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Attili I, Passaro A, Pisapia P, Malapelle
U and de Marinis F: Uncommon EGFR compound mutations in non-small
cell lung cancer (NSCLC): A systematic review of available
evidence. Curr Oncol. 29:255–266. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Russo A, Franchina T, Ricciardi G,
Battaglia A, Picciotto M and Adamo V: Heterogeneous responses to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in patients with uncommon EGFR mutations: New insights and
future perspectives in this complex clinical scenario. Int J Mol
Sci. 20(1431)2019.PubMed/NCBI View Article : Google Scholar
|
